Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 3.6% Higher – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 3.6% during mid-day trading on Wednesday . The company traded as high as $7.34 and last traded at $7.24. Approximately 13,659,767 shares were traded during trading, an increase of 100% from the average daily volume of 6,818,902 shares. The stock had previously closed at $6.99.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of analyst reports. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Jefferies Financial Group lowered their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $2.08 billion, a price-to-earnings ratio of -4.73 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $6.77 and its 200 day moving average price is $7.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business earned ($0.43) EPS. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the completion of the sale, the chief financial officer now directly owns 1,426,506 shares in the company, valued at $9,015,517.92. This trade represents a 1.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,647,966. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 107,788 shares of company stock worth $724,691. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its position in shares of Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after acquiring an additional 288,926 shares during the last quarter. FMR LLC boosted its position in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the period. State Street Corp grew its holdings in Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares in the last quarter. Perceptive Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at $5,769,000. Finally, Pier 88 Investment Partners LLC boosted its position in Recursion Pharmaceuticals by 442.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock worth $882,000 after acquiring an additional 109,210 shares during the period. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.